Worth reading
57In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Avoiding a definitive answer
How definitive the wording is.Items stated in the management plan
Annual updateNet Sales-39.8%
基準 113Target68million (business revenue)
Operating profit+10.3%
基準 -397Target-356million
Net income for the current fiscal year+16.9%
基準 -362Target-301million
Each line is the climb from the baseline the document states to the target it sets. The slope is scaled against the largest climb in this document. The increase shown by the dotted line is calculated from the two reported figures because the company did not provide the amount of growth.
What happened to the previous planBusiness revenue 113, operating profit (397), ordinary profit (360), net income (362) (fiscal year ending March 2026 plan) → Business revenue 68, operating profit (356), ordinary profit (300), net income (301) (actual results for the fiscal year ending March 2026)（Business revenue: 60% of plan; others: "-"）0.0%Calculated from the two disclosed figures
Investment amount by sectorField Phase III trials in the cancer field / Amount ¥990 million, Field Phase II trials in the cancer field / Amount ¥570 million, Field XPRIZE Healthspan (semi-Final） / Amount ¥110 million, Field XPRIZE Healthspan (Final） / Amount ¥590 million, Field Nonclinical trials for anti-aging diseases / Amount ¥250 million, Field Veterinary drug development / Amount ¥200 million, Field Active pharmaceutical ingredient costs / Amount ¥180 million, Field Drug formulation costs / Amount ¥150 million
Key initiatives
01Early approval and expansion of indications in the cancer field, plus development of the anti-aging and longevity businesses and other operations
02Complete the ongoing Phase III trials and commercialize the products
03Expand indications to cancers other than those listed above
04Conduct nonclinical and clinical trials in dogs and cats
05Complete the semifinal trial in XPRIZE Healthspan and apply for the final (April 2026)
06If the team places among the top 10 in August 2026, conduct the final trial (January 2027 to December 2029).
07Expand indications to other age-related diseases
08Expand into overseas markets, including the United States, Taiwan, and Saudi Arabia
09Put cutting-edge longevity medicine into practical use in society, including pharmaceuticals, artificial intelligence, and other applications
10Rare cancers (Phase III)
11Expansion into major cancers (Phase II)
12Focus on the international longevity competition XPRIZE Healthspan
13Expand into diseases affecting the sensory organs, bones, and muscles associated with aging, as well as veterinary pharmaceuticals
14Diversify overall risk by advancing these initiatives in parallel with the pharmaceutical business
Plan assumptionsThe assumed TAM is calculated as the number of patients in the target segment multiplied by the daily price of a comparable product and the assumed number of dosing days, without taking the medication adherence rate or the market share of our products into account. Assuming that the price of COVID-19 drugs is calculated using the same method as comparable drugs tocilizumab, prices for CML, melanoma, and non-small cell lung cancer are applied. The XPRIZE Healthspan final trial will be conducted if the team places among the top 10.
Non-financial targetsIndicator Number of clinical trials / Target value 7 / Timing Fiscal year ending March 2027, Indicator Selection as one of the top 10 finalists in XPRIZE Healthspan / Target value Top 10 teams / Timing August 2026, Indicator XPRIZE Healthspan final trial / Target value Approximately 150 participants (75 active-drug, 75 placebo) / Timing January 2027 to December 2029 (if selected among the top 10), Indicator Agreement rate with specialists for AI supporting diabetes treatment / Target value More than 80% / Timing Not disclosed
Size of the Target MarketSubject Chronic myeloid leukemia (CML) / Market Size ¥89.0 billion in Japan; ¥950.0 billion in the United States / Source Ministry of Health, Labour and Welfare, 2020 Patient Survey; NIH, "Cancer Stat Facts: Leukemia — Chronic Myeloid Leukemia (CML)", Subject Malignant melanoma / Market Size ¥15.0 billion in Japan; ¥1.1 trillion in the United States / Source Not disclosed, Subject Non-small cell lung cancer (NSCLC) / Market Size ¥490.0 billion in Japan; ¥3.1 trillion in the United States / Source Not disclosed, Subject Pancreatic cancer / Market Size ¥68.0 billion in Japan; ¥570.0 billion in the United States / Source Not disclosed, Subject Ultra-thin endoscope (peritoneal dialysis) / Market Size ¥1.6 billion in Japan / Source Not disclosed, Subject AI supporting maintenance hemodialysis care / Market Size ¥2.6 billion in Japan / Source Not disclosed, Subject AI supporting diabetes treatment / Market Size ¥4.2 billion in Japan / Source Not disclosed, Subject AI for diagnosing impaired swallowing function / Market Size ¥4.1 billion in Japan / Source Not disclosed, Subject Companion animals / Market Size $25.4 billion in 2025; $56.4 billion in 2033; CAGR 10.6% / Source Not disclosed
Risks identified by the company
Dependence on key individuals
Revenue uncertainty
Research and development uncertainty
Liquidity
Reason for revision or withdrawal
A change in the presentation classification of subsidy income from NIBIOHN, a delay in the start of Eirion Therapeutics' Phase II trial, lower cost of sales for malignant melanoma, reduced research and development expenses for CML and pancreatic cancer, and expenses related to a third-party allotment, among other factors.
| Item | Details |
|---|---|
| Plan name | Fiscal 2026 Business Plan and Growth Potential |
| Plan period | Fiscal 2026 (fiscal year ending March 2027) |
| Progress against the plan | Annual update |
| Sales Target | ¥113 million (business revenue) → ¥68 million (business revenue)（60% (versus plan)） |
| Operating profit target | ¥-397 million → ¥-356 million |
| Net income target | ¥-362 million → ¥-301 million |
| Investment amount by sector | Field Phase III trials in the cancer field / Amount ¥990 million, Field Phase II trials in the cancer field / Amount ¥570 million, Field XPRIZE Healthspan (semi-Final） / Amount ¥110 million, Field XPRIZE Healthspan (Final） / Amount ¥590 million, Field Nonclinical trials for anti-aging diseases / Amount ¥250 million, Field Veterinary drug development / Amount ¥200 million, Field Active pharmaceutical ingredient costs / Amount ¥180 million, Field Drug formulation costs / Amount ¥150 million |
| Non-financial targets | Indicator Number of clinical trials / Target value 7 / Timing Fiscal year ending March 2027, Indicator Selection as one of the top 10 finalists in XPRIZE Healthspan / Target value Top 10 teams / Timing August 2026, Indicator XPRIZE Healthspan final trial / Target value Approximately 150 participants (75 active-drug, 75 placebo) / Timing January 2027 to December 2029 (if selected among the top 10), Indicator Agreement rate with specialists for AI supporting diabetes treatment / Target value More than 80% / Timing Not disclosed |
| Plan assumptions | The assumed TAM is calculated as the number of patients in the target segment multiplied by the daily price of a comparable product and the assumed number of dosing days, without taking the medication adherence rate or the market share of our products into account. Assuming that the price of COVID-19 drugs is calculated using the same method as comparable drugs tocilizumab, prices for CML, melanoma, and non-small cell lung cancer are applied. The XPRIZE Healthspan final trial will be conducted if the team places among the top 10. |
| Key initiatives | Early approval and expansion of indications in the cancer field, plus development of the anti-aging and longevity businesses and other operations, Complete the ongoing Phase III trials and commercialize the products, Expand indications to cancers other than those listed above, Conduct nonclinical and clinical trials in dogs and cats, Complete the semifinal trial in XPRIZE Healthspan and apply for the final (April 2026), If the team places among the top 10 in August 2026, conduct the final trial (January 2027 to December 2029)., Expand indications to other age-related diseases, Expand into overseas markets, including the United States, Taiwan, and Saudi Arabia, Put cutting-edge longevity medicine into practical use in society, including pharmaceuticals, artificial intelligence, and other applications, Rare cancers (Phase III), Expansion into major cancers (Phase II), Focus on the international longevity competition XPRIZE Healthspan, Expand into diseases affecting the sensory organs, bones, and muscles associated with aging, as well as veterinary pharmaceuticals, Diversify overall risk by advancing these initiatives in parallel with the pharmaceutical business |
| Results under the previous plan | Business revenue 113, operating profit (397), ordinary profit (360), net income (362) (fiscal year ending March 2026 plan) → Business revenue 68, operating profit (356), ordinary profit (300), net income (301) (actual results for the fiscal year ending March 2026)（Business revenue: 60% of plan; others: "-"） |
| Reason for revision or withdrawal | A change in the presentation classification of subsidy income from NIBIOHN, a delay in the start of Eirion Therapeutics' Phase II trial, lower cost of sales for malignant melanoma, reduced research and development expenses for CML and pancreatic cancer, and expenses related to a third-party allotment, among other factors. |
| Size of the Target Market | Subject Chronic myeloid leukemia (CML) / Market Size ¥89.0 billion in Japan; ¥950.0 billion in the United States / Source Ministry of Health, Labour and Welfare, 2020 Patient Survey; NIH, "Cancer Stat Facts: Leukemia — Chronic Myeloid Leukemia (CML)", Subject Malignant melanoma / Market Size ¥15.0 billion in Japan; ¥1.1 trillion in the United States / Source Not disclosed, Subject Non-small cell lung cancer (NSCLC) / Market Size ¥490.0 billion in Japan; ¥3.1 trillion in the United States / Source Not disclosed, Subject Pancreatic cancer / Market Size ¥68.0 billion in Japan; ¥570.0 billion in the United States / Source Not disclosed, Subject Ultra-thin endoscope (peritoneal dialysis) / Market Size ¥1.6 billion in Japan / Source Not disclosed, Subject AI supporting maintenance hemodialysis care / Market Size ¥2.6 billion in Japan / Source Not disclosed, Subject AI supporting diabetes treatment / Market Size ¥4.2 billion in Japan / Source Not disclosed, Subject AI for diagnosing impaired swallowing function / Market Size ¥4.1 billion in Japan / Source Not disclosed, Subject Companion animals / Market Size $25.4 billion in 2025; $56.4 billion in 2033; CAGR 10.6% / Source Not disclosed |
| Risks identified | Dependence on key individuals, Revenue uncertainty, Research and development uncertainty, Liquidity |
| Publication date | 25 May 2026 |
Items this document does not state (10)
Operating profit margin targetROE targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceTotal investment planSegment targetDate of board resolution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Business revenue for the fiscal year ending March 2026 fell below plan due to factors including a change in the presentation classification of subsidy income from the National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN) and a delay in the start of Eirion Therapeutics' Phase II trial. Meanwhile, the operating loss was smaller than planned due to lower cost of sales for malignant melanoma and reduced research and development expenses.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.